LEADER 03057nam  22005175  450 
001 9910300220603321
005 20200701021507.0
010   $a1-907673-91-1
024 7 $a10.1007/978-1-907673-91-7
035   $a(CKB)3710000000433258
035   $a(EBL)2094030
035   $a(OCoLC)910935532
035   $a(SSID)ssj0001524803
035   $a(PQKBManifestationID)11979175
035   $a(PQKBTitleCode)TC0001524803
035   $a(PQKBWorkID)11484903
035   $a(PQKB)10379782
035   $a(DE-He213)978-1-907673-91-7
035   $a(MiAaPQ)EBC2094030
035   $a(PPN)186394462
035   $a(EXLCZ)993710000000433258
100   $a20150609d2015      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aAtlas of Rheumatoid Arthritis /$fedited by Paul Emery
205   $a1st ed. 2015.
210  1$aTarporley :$cSpringer Healthcare Ltd. :$cImprint: Springer Healthcare,$d2015.
215   $a1 online resource (269 p.)
300   $aDescription based upon print version of record.
311   $a1-907673-90-3 
320   $aIncludes bibliographical references at the end of each chapters.
327   $aClassification of rheumatoid arthritis -- Pre-rheumatoid arthritis -- Early rheumatoid arthritis -- Established rheumatoid arthritis -- Remission and rheumatoid arthritis -- Magnetic resonance imaging in rheumatoid arthritis -- Ultrasound imaging in rheumatoid arthritis -- Dual energy X-ray absorptiometry in rheumatoid arthritis -- Methotrexate -- Immunotherapy -- Rituximab.- Novel therapies in rheumatoid arthritis: small molecules.
330   $aAtlas of Rheumatoid Arthritis is a high-quality educational initiative, written by leaders in the field of rheumatology, containing a collection of approximately 150 relevant images, with extended descriptive captions and a comprehensive bibliography. The Atlas of Rheumatoid Arthritis will provide clinicians with a visual guide to rheumatoid arthritis, focusing on assessment, diagnosis and treatment, including newer research into the signalling pathways involved in the pathogenesis of RA, before focusing on the treatment of RA. Rheumatoid arthritis (RA) is the most common and most serious of the inflammatory arthritic disorders, and it dominates clinical rheumatological practice. Effective, early treatment is vital as this can slow the course of the disease and reduce joint damage. RA is usually treated using disease-modifying anti-rheumatic drugs (DMARDs), most commonly methotrexate. The newest treatments target the disease-causing immune elements specifically and directly.
606   $aRheumatology
606   $aRheumatology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33170
615  0$aRheumatology.
615 14$aRheumatology.
676   $a616.991
702   $aEmery$b Paul$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910300220603321
996   $aAtlas of Rheumatoid Arthritis$91759946
997   $aUNINA